Sanofi’s Amlitelimab delivers in Phase 3 trials, heads for global filings
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Subscribe To Our Newsletter & Stay Updated